Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation (NITA)

2 maggio 2008 aggiornato da: University of Minnesota

A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients

This study was designed to test the safety and efficacy of up to 3 pancreatic alloislet transplants in type 1 diabetic patients with hypoglycemia unawareness. 6 subjects were transplanted under this protocol using anti-thymocyte globulin induction immunosuppression and everolimus with cyclosporine maintenance immunosuppression.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a Phase I/II study designed to assess the safety and efficacy of sequential islet allotransplantation for the reestablishment of stable glycemic control in type 1 diabetic recipients. A total of 6 patients with type 1 diabetes have received up to three transplants of islets from different donor pancreases.

Potential candidates for islet allotransplantation included patients age 18 and older with type 1 diabetes. Induction immunotherapy for the first transplant consisted of anti-thymocyte globulin; basiliximab was used for any subsequent transplants. Peritransplant anti-inflammatory treatment with etanercept was given for each islet transplant. Maintenance immunosuppression is with cyclosporine and RAD. It is felt that those patients in whom metabolic lability/instability, reduced awareness of hypoglycemia, poor glycemic control, and progressive secondary complications persist despite continued and intensive efforts made in close cooperation with their diabetes care team are particularly likely to have a favorable benefit/risk ratio.

Adverse events, irrespective of their presumed relationship to the transplantation of allogeneic islets and/or protocol-regulated treatment products (concomitant therapy), are being monitored and recorded throughout the first year after the final islet transplant.

The proportion of single and sequential donor islet allograft recipients with full (insulin independence and HbA1c <7%) and partial (insulin dependence, basal or arginine-stimulated C-peptide levels of greater or equal to 0.5 ng/mL and HbA1c <7%) islet graft function at one year after the final islet transplant will be assessed. The impact of islet transplantation on quality of life will also be assessed.

The predictive value for posttransplant insulin independence of factors such as insulin resistance before and at intervals after pancreatectomy, cellular composition of the transplant, number of beta cells transplanted; and viability and insulin secretory response of isolated islets are being assessed.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

6

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Stati Uniti
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • University of Minnesota

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Primary islet allotransplant
  • Patients with type 1 diabetes mellitus under intensive insulin management
  • Age 18 or older
  • Ability to give written informed consent

Exclusion Criteria:

  • Age less than 18 years.
  • BMI >26 kg/m2.
  • Insulin requirement of > 50 IU per day.
  • Positive C-peptide response to intravenous arginine stimulation.
  • Untreated proliferative retinopathy.
  • Creatinine clearance < 60 ml/min/1.73 m2 for females and 70 ml/min/1.73 m2 for males.
  • Serum creatinine >1.3 mg/dl for females, >1.5 mg/dl for males.
  • Previous pancreas or islet transplant.
  • Presence of history of panel-reactive anti-HLA antibodies >10%.
  • Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures.
  • Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment for suspected TB).
  • Negative screen for Epstein-Barr Virus (EBV).
  • Invasive aspergillus infection within year prior to study entry.
  • History of malignancy.
  • Active alcohol or substance abuse
  • History of non-adherence to prescribed regimens.
  • Psychiatric disorder making the subject not a suitable candidate for transplantation.
  • Inability to provide informed consent.
  • Baseline Hgb < 11.7 g/dl in females, or < 13 g/dl in males; lymphopenia (<1,000/microL), or leukopenia (<3,000 total leukocytes/microL), or an absolute CD4+ count <500/microL., or platelets <150,000/microL
  • History of coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or patient with INR >1.5.
  • Severe co-existing cardiac disease.
  • Baseline liver function tests outside of normal range or history of significant liver disease.
  • Active peptic ulcer disease.
  • Severe unremitting diarrhea or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications.
  • Presence of severe allergy requiring acute or chronic treatment, or hypersensitivity to drugs similar to RAD (e.g., macrolides).
  • Known hypersensitivity to rabbit proteins.
  • Hyperlipidemia (fasting LDL cholesterol > 130 mg/dl, treated or untreated; and/or fasting triglycerides > 200 mg/dl).
  • Addison's disease.
  • Under treatment requiring chronic use of systemic steroids.
  • Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: 1
Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
Biologico: Allogeneic Islets of Langerhans
Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
Altri nomi:
  • Isolotti
Droga: Everolimus
Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
Altri nomi:
  • Rad
Droga: anti-thymocyte globulin
A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
Altri nomi:
  • ATG
  • Thymogloblin
Droga: Cyclosporine
Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
Altri nomi:
  • Neorale

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
• The incidence, timing, and severity of adverse events during one year after the first and any subsequent islet transplants.
Lasso di tempo: 1 year
1 year
• Incidence and severity of hypoglycemia during the first year after the first and any subsequent islet transplants.
Lasso di tempo: 1 yr
1 yr
• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.
Lasso di tempo: 1 year
1 year

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
• The proportion of subjects who achieve insulin independence in the first year after single-donor or sequential transplantation.
Lasso di tempo: 1 year
1 year
• The proportion of islet allograft recipients with full and partial islet graft function at one year after the most recent islet transplant.
Lasso di tempo: 1 year
1 year
• Glycemic control and insulin secretory responses during the first year after the first and any subsequent transplants.
Lasso di tempo: 1 year
1 year
• The effect of donor age, pretransplant islet insulin secretory response in vitro, number of transplanted islet equivalents (IEQ), number of transplanted beta cells, pretransplant recipient insulin requirements and action, recipient body mass index (BM
Lasso di tempo: Day of transplant
Day of transplant
• The impact of islet transplantation on the quality of life of transplant recipients.
Lasso di tempo: 1 year
1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

University of Minnesota

Collaboratori

Novartis
Juvenile Diabetes Research Foundation
National Institutes of Health (NIH)

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 marzo 2003

Completamento primario (Effettivo)

1 agosto 2006

Completamento dello studio (Effettivo)

1 agosto 2006

Date di iscrizione allo studio

Primo inviato

2 febbraio 2006

Primo inviato che soddisfa i criteri di controllo qualità

2 febbraio 2006

Primo Inserito (Stima)

3 febbraio 2006

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

8 maggio 2008

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 maggio 2008

Ultimo verificato

1 maggio 2008

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 0207M29841

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi